Ibandronic Acid Sandoz
ibandronic acid
Table of contents
Overview
This is a summary of the European public assessment report (EPAR) for Ibandronic Acid Sandoz. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Ibandronic Acid Sandoz.
Authorisation details
Product details | |
---|---|
Name |
Ibandronic Acid Sandoz
|
Agency product number |
EMEA/H/C/002367
|
Active substance |
ibandronic acid
|
International non-proprietary name (INN) or common name |
ibandronic acid
|
Therapeutic area (MeSH) |
|
Anatomical therapeutic chemical (ATC) code |
M05BA06
|
Generic |
This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see Generic and hybrid medicines. |
Publication details | |
---|---|
Marketing-authorisation holder |
Sandoz GmbH
|
Revision |
9
|
Date of issue of marketing authorisation valid throughout the European Union |
26/07/2011
|
Contact address |
Biochemiestrasse 10 |
Product information
06/07/2022 Ibandronic Acid Sandoz - EMEA/H/C/002367 - N/0021
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Pharmacotherapeutic group
-
Drugs for treatment of bone diseases
-
Bisphosphonates
Therapeutic indication
Ibandronic acid Sandoz is indicated for the prevention of skeletal events (pathological fractures, bone complications requiring radiotherapy or surgery) in patients with breast cancer and bone metastases.